RxDoctor Payments Data

William Kleinschrodt, MD

Internal Medicine · Mobile, ALNPI 1396786836

Payments from drug & device makers

$8,994in general payments, 2019–2025

Across 637 payments — averaging $14.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$959
  • Novartis$842
  • Takeda Pharmaceuticals U.S.A., Inc.$777
  • AbbVie$710
  • Bayer$668
  • AstraZeneca$656
  • plus $4K from 36 others

What the payments were for

  • Food & beverage$8,986100%
  • Education$80%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$8,994 in reported general payments places this provider in the 90th percentile of 1,533 internal medicine providers in Alabama.

See all internal medicine providers in Alabama

Medicare billing

Part B allowed, 2024
$187,640
Medicare patients
279
Services billed
5,825

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide247$275,744
EliquisApixaban205$184,604
FarxigaDapagliflozin Propanediol116$128,886
RybelsusSemaglutide84$126,688
MounjaroTirzepatide109$115,766
JardianceEmpagliflozin81$108,021
TrulicityDulaglutide60$84,339
XareltoRivaroxaban59$64,700
LinzessLinaclotide52$44,027
Soliqua 100-33Insulin Glargine/Lixisenatide38$42,967
JanuviaSitagliptin Phosphate47$37,325
Trelegy ElliptaFluticasone/Umeclidin/Vilanter35$35,534
EntrestoSacubitril/Valsartan29$23,769
MyrbetriqMirabegron17$20,001
KerendiaFinerenone29$18,393

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$959$402,432331 claims
Lilly USA, LLCMounjaro, Trulicity$591$200,105169 claims
PfizerEliquis$625$184,604205 claims
Boehringer IngelheimJardiance, Tradjenta, Stiolto Respimat$192$137,990120 claims
AstraZenecaFarxiga, Breztri Aerosphere$656$136,755128 claims
Johnson & JohnsonXarelto$599$64,70059 claims
MerckJanuvia, Janumet Xr$220$46,18959 claims
AbbVieLinzess$710$44,02752 claims
Sanofi-aventis U.S. LLCSoliqua 100-33$205$42,96738 claims
GSKTrelegy Ellipta, Breo Ellipta$421$42,56647 claims
NovartisEntresto$842$23,76929 claims
Astellas Pharma US IncMyrbetriq$68$20,00117 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,533 internal medicine providers in Alabama.

Other internal medicine in Mobile

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →